BioNTech Historical Balance Sheet
BNTX Stock | USD 120.72 2.18 1.84% |
Trend analysis of BioNTech SE balance sheet accounts such as Total Assets of 24.2 B, Short and Long Term Debt Total of 162.4 M or Other Current Liab of 744.1 M provides information on BioNTech's total assets, liabilities, and equity, which is the actual value of BioNTech SE to its prevalent stockholders. By breaking down trends over time using BioNTech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.
BioNTech Inventory |
|
BioNTech |
About BioNTech Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of BioNTech SE at a specified time, usually calculated after every quarter, six months, or one year. BioNTech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioNTech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioNTech currently owns. An asset can also be divided into two categories, current and non-current.
BioNTech Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of BioNTech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioNTech SE books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on BioNTech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNTech SE are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Additional Paid In Capital
Additional Paid In Capital (or APIC) is an accounting term found on BioNTech SE Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x BioNTech Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of BioNTech SE shares and does not have any impact on the value of APIC. The excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most accounts from BioNTech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Other Assets are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 17.4 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 162.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 301.5M | 212.2M | 219.1M | 162.4M | Total Assets | 15.8B | 23.3B | 23.0B | 24.2B |
BioNTech balance sheet Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Short Long Term Debt Total | 76.5M | 240.2M | 301.5M | 212.2M | 219.1M | 162.4M | |
Other Current Liab | 16.4M | 487.6M | 1.6B | 2.1B | 1.1B | 744.1M | |
Total Current Liabilities | 138.1M | 606.0M | 3.5B | 3.0B | 2.1B | 1.3B | |
Total Stockholder Equity | 493.5M | 1.4B | 11.9B | 20.1B | 20.2B | 21.3B | |
Other Liab | 205.6M | 97.1M | 109.7M | 283.9M | 326.5M | 166.9M | |
Net Tangible Assets | 179.6M | 406.5M | 1.2B | 11.7B | 13.5B | 14.1B | |
Property Plant And Equipment Net | 148.1M | 326.0M | 520.4M | 821.1M | 971.6M | 1.0B | |
Current Deferred Revenue | 93.6M | 391.5M | 189.1M | 77.1M | 353.3M | 371.0M | |
Net Debt | (450.2M) | (970.0M) | (1.4B) | (13.7B) | (11.4B) | (10.9B) | |
Retained Earnings | (424.8M) | (409.6M) | 9.9B | 18.8B | 19.8B | 20.8B | |
Accounts Payable | 20.5M | 102.3M | 160M | 204.1M | 354M | 371.7M | |
Cash | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
Non Current Assets Total | 237.5M | 651.7M | 758.5M | 1.4B | 3.5B | 3.7B | |
Non Currrent Assets Other | 2K | 1.0M | 800K | 6.5M | 187.1M | 196.5M | |
Other Assets | 2.4M | 168.2M | 22.2M | 249.2M | 286.6M | 300.9M | |
Long Term Debt | 68.9M | 231.0M | 171.6M | 176.2M | 191M | 116.1M | |
Cash And Short Term Investments | 520.8M | 1.3B | 2.1B | 14.1B | 16.5B | 17.4B | |
Net Receivables | 20.2M | 166.4M | 12.4B | 7.1B | 2.2B | 3.0B | |
Good Will | 3.0M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | |
Common Stock Total Equity | 166.8M | 193.3M | 232.3M | 246.3M | 283.3M | 185.2M | |
Common Stock Shares Outstanding | 211.5M | 248.5M | 259.7M | 249.8M | 242.7M | 229.1M | |
Short Term Investments | 1.7M | 137.2M | 381.6M | 189.4M | 4.9B | 5.1B | |
Liabilities And Stockholders Equity | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Non Current Liabilities Total | 166.0M | 340.8M | 455.5M | 272.9M | 689.9M | 378.2M | |
Inventory | 11.7M | 64.1M | 502.5M | 439.6M | 357.7M | 190.9M | |
Other Current Assets | 1.2M | 392.6M | 113.8M | 272.3M | 460M | 483M | |
Other Stockholder Equity | (5.5M) | 1.8B | (3.8M) | (5.3M) | (10.8M) | (10.3M) | |
Total Liab | 304.2M | 946.8M | 3.9B | 3.2B | 2.8B | 1.7B | |
Property Plant And Equipment Gross | 148.1M | 326.0M | 594.6M | 821.1M | 1.2B | 1.2B | |
Total Current Assets | 560.2M | 1.7B | 15.1B | 21.9B | 19.5B | 20.5B | |
Accumulated Other Comprehensive Income | 691.5M | 25.5M | 1.8B | 979.3M | 244.8M | 232.6M | |
Short Term Debt | 7.6M | 15.2M | 129.9M | 36M | 56.2M | 37.6M | |
Intangible Assets | 86.5M | 109.8M | 144.6M | 158.5M | 781.7M | 820.8M | |
Common Stock | 232.3M | 246.3M | 246.3M | 248.6M | 285.9M | 218.0M | |
Property Plant Equipment | 116.0M | 148.1M | 326.0M | 520.4M | 598.5M | 628.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.